1432 J. Am. Chem. Soc., Vol. 121, No. 7, 1999
Robins et al.
84.15, 84.28, 95.77, 102.70, 114.83, 143.10, 149.59, 162.71; HRMS
(FAB) m/z 344.1097 (48, MH+ ) 344.1094). Anal. Calcd for
C13H17N3O8 (343.3): C, 45.48; H, 4.99; N, 12.24. Found: C, 45.64;
H, 5.06; N, 12.15.
9-(5-Deoxy-3-deuterio-2,3-O-isopropylidene-â-D-ribo-hexofurano-
syl)adenine (3′-[2H]28a). Treatment of 27a (0.03 mmol, 11 mg) by
procedure C [with chromatography (8% MeOH/CH2Cl2)] gave 28a/
1
3′-[2H]28a (∼1:1; 8 mg, 83%): UV max 259 nm; H NMR (Me2SO-
d6) δ 4.20 (t, J ) 7.1 Hz, 1, H4′), 4.87 (dd, J ) 6.2, 3.3 Hz, 0.50,
H3′), 5.47 (d, J ) 2.7 Hz, 1, H2′), other peaks same as in the spectrum
of 28a; the 13C NMR (Me2SO-d6) peak at δ 83.71 (C3′) was reduced
to ∼50% intensity; HRMS (FAB) m/z 322.1511 (100, MH+ [C14H20N5O4]
) 322.1515), 323.1583 (98, MH+ [C14H19DN5O4] ) 323.1578).
1-(5-Deoxy-3-deuterio-â-D-ribo-hexofuranosyl)uracil (3′-[2H]21b)
and 1-(5-Deoxy-3-deuterio-â-D-xylo-hexofuranosyl)uracil (3′-[2H]22).
Treatment of 18b (12 mg, 0.04 mmol) by procedure C [DMAC (1 mL)
added for solubility] [with chromatography (15% MeOH/CH2Cl2)]
followed by RP-HPLC (15 f 40% CH3CN/H2O; 2.8 mL/min, 60 min)
gave 3′-[2H]21b and 3′-[2H]22 (9 mg, 87%; ∼1.3:1). Data for 3′-[2H]-
1-(5-Deoxy-3-deuterio-2,3-O-isopropylidene-â-D-ribo-hexofurano-
syl)uracil (3′-[2H]21a). Procedure C. A solution of 18a (10 mg, 0.03
mmol), Bu3SnD (40 µL, 44 mg, 0.15 mmol), and AIBN (∼2 mg) in
dried benzene (5 mL) was deoxygenated (Ar, 20 min) and then heated
for 1 h at reflux. Volatiles were evaporated, and the residue was
chromatographed (5% MeOH/CH2Cl2) to give 21a/3′-[2H]21a (∼1:4;
1
7.5 mg, 86%): UV max 259 nm; H NMR δ 4.20 (t, J ) 6.5 Hz, 1,
H4′), 4.76 (“t”, J ) 6.5, 5.0 Ηz, ∼0.2, H3′), 4.99 (d, J ) 2.0 Hz, 1,
H2′), other peaks same as for 21a; MS (CI) m/z 300 (100, MH+ [3′-
[2H]21a]), 299 (22, MH+ [21a]).
1-(5-Deoxy-6-O-nitro-â-D-ribo-hexofuranosyl)uracil (18b). A solu-
tion of the residue (EtOAc) from deprotection of 18a (68 mg, 0.2 mmol)
by procedure A was washed (saturated NaHCO3/H2O, brine) and dried
(Na2SO4). Volatiles were evaporated, and the residue was chromato-
graphed (7% MeOH/CH2Cl2) to give 18b (55 mg, 90%) as a white
solid: mp 161-162.5 °C; UV (MeOH) max 261 nm; 1H NMR (Me2SO-
d6) δ 2.06-2.14 (m, 2H), 3.82-3.88 (m, 2H), 4.12 (“q”, J = 5.0 Hz,
1H), 4.62 (dd, J ) 10.6, 6.4 Hz, 2H), 5.23 (d, J ) 5.2 Hz, 1H, ex),
5.45 (d, J ) 5.5 Hz, 1H, ex), 5.64 (d, J ) 8.0 Hz, 1H), 5.72 (d, J )
4.9 Hz, 1H), 7.63 (d, J ) 8.0 Hz, 1H), 11.38 (br s, 1H, ex); 13C NMR
(Me2SO-d6) δ 30.00, 70.78, 72.43, 72.86, 79.68, 89.24, 102.03, 141.44,
150.62, 163.05; HMRS (CI) m/z 304.0789 (6, MH+ [C10H14N3O8] )
304.0781).
9-(5-Deoxy-â-D-ribo-hexofuranosyl)adenine (28b). A solution of
9-(2-O-acetyl-3,6-di-O-benzoyl-5-deoxy-â-D-ribo-hexofuranosyl)-
adenine17b (531 mg, 1 mmol) in NH3/MeOH (10 mL) was stirred in a
sealed flask overnight at ambient temperature. Volatiles were evapo-
rated, and the residue was dissolved (H2O) and washed (CH2Cl2, 3×).
The aqueous phase was evaporated, and the residue was recrystallized
(H2O) to give 28b (234 mg, 83%): mp 230-232 °C (lit.48 mp 231.5-
232.5 °C); UV max 260 (ꢀ 15 200); 1H NMR (Me2SO-d6) δ 1.79 (dd,
J ) 12.2, 7.1 Hz, 2H), 3.45 (dd, J ) 10.8, 5.4 Hz, 2H), 4.00 (td, J )
7.1, 4.8 Hz, 1H), 4.09 (“q”, J = 4.8 Hz, 1H), 4.48 (t, J ) 5.0 Hz, 1H,
ex), 4.66 (q, J ) 5.2 Hz, 1H), 5.17 (d, J ) 4.8 Hz, 1H, ex), 5.41 (d,
J ) 5.2 Hz, 1H, ex), 5.82 (d, J ) 5.2 Hz, 1H), 7.28 (br s, 2H, ex), 8.12
(s, 1H), 8.30 (s, 1H); 13C NMR (Me2SO-d6) δ 36.57, 57.57, 72.98,
73.48, 81.08, 87.50, 119.28, 140.03, 149.59, 152.81, 156.22; MS (CI)
m/z 282 (42, MH+), 136 (100).
1
21b: UV max 261 nm; H NMR (Me2SO-d6) no peak at δ 3.79 (H3′
2
f H3′), 3.86 (dd, J ) 7.0, 5.0 Hz, 1, H4′), 4.05 (t, J ) 5.0 Hz, 1,
H2′), other peaks same as those for 21b; 13C NMR (Me2SO-d6) peaks
same as those for 21b except no peak at δ 72.93 (C3′); HRMS (FAB)
m/z 259.0900 (23, M+ [C10H13DN2O6] ) 259.0915). Data for 3′-[2H]-
22: UV max 260 nm; 1H NMR (Me2SO-d6) no peak at δ 3.79 (H3′ f
2H3′), 3.96 (t, J ) 4.0 Hz, 1, H2′), 4.24 (t, J ) 6.6 Hz, 1, H4′), other
peaks same as those for 22; 13C NMR (Me2SO-d6) peaks same as those
for 22 except no peak at δ 75.44 (C3′); HRMS (FAB) m/z 259.0933
(10, M+ [C10H13DN2O6] ) 259.0915).
A sample of 18b (17 mg) was treated as described, except the first
evaporation residue was partitioned (CH2Cl2/H2O). The aqueous phase
was evaporated, and the residue was subjected to RP-HPLC as described
to give uracil (∼5%; tR ) 24.4 min), 3′-[2H]21b (∼50%; tR ) 27.7
min), 3′-[2H]22 (∼36%; tR ) 31.4 min), and an unidentified product
(∼7%; tR ) 34.3 min). This unidentified product decomposed im-
mediately to give uracil upon addition of TBAF/THF.
1-(5-Deoxy-â-D-xylo-hexofuranosyl)uracil (22). A solution of
1-(2,3,6-tri-O-acetyl-5-deoxy-â-D-xylo-hexofuranosyl)uracil (26; 384
mg, 1 mmol) in NH3/MeOH (10 mL) was stirred in a sealed flask
overnight at ambient temperature. Volatiles were evaporated, and the
residue was chromatographed (15% MeOH/CH2Cl2) and recrystallized
(EtOH) to give 22 (215 mg, 83%): mp 159-160.5 °C; UV max 262
1
nm (ꢀ 10 200); H NMR (Me2SO-d6) δ 1.84 (dd, J ) 13.2, 6.6 Hz,
2H), 3.53 (dd, J ) 11.3, 5.1 Hz, 2H), 3.79 (dd, J ) 3.4, 2.8 Hz, 1H),
3.96 (t, J ) 4.0 Hz, 1H), 4.24 (td, J ) 6.6, 2.8 Hz, 1H), 4.57 (t, J )
5.1 Hz, 1H, ex), 5.39 (d, J ) 3.4 Hz, 1H, ex), 5.60 (d, J ) 4.0 Hz, 1H,
ex), 5.65 (d, J ) 8.1 Hz, 1H), 5.78 (d, J ) 4.0 Hz, 1H), 7.72 (d, J )
8.1 Hz, 1H), 11.29 (br s, 1H, ex); 13C NMR (Me2SO-d6) δ 31.68, 58.11,
75.44, 80.56, 81.35, 91.19, 101.03, 141.69, 150.75, 163.54; HRMS
(FAB) m/z 259.0935 (100, MH+ [C10H15N2O6] ) 259.0930). Anal.
Calcd for C10H14N2O6 (258): C, 46.51; H, 5.46; N, 10.85. Found: C,
46.40; H, 5.69; N, 10.69.
9-(5-Deoxy-2,3-O-isopropylidene-â-D-ribo-hexofuranosyl)ade-
nine (28a). Treatment of 28b (100 mg, 0.35 mmol) as described for
21b f 21a [with concentrated NH3/H2O (2 mL) in place of NaHCO3]
and evaporation of volatiles gave a residue that was slurried with
EtOAc/acetone (1:1). Filtration of the suspension, evaporation of the
filtrate, and chromatography (8% MeOH/CH2Cl2) and recrystallization
(MeOH) of the residue gave 28a (94 mg, 82%): mp 269-271 °C dec
9-(5-Deoxy-â-D-xylo-hexofuranosyl)adenine (29). Bu3SnH (41 µL,
44.6 mg, 0.15 mmol) and AIBN (∼2 mg) were added to 27b (10 mg,
0.03 mmol) in DMAC (1 mL) and dried benzene (9 mL). The solution
was deoxygenated (Ar, 20 min) and heated at reflux for 2 h [AIBN
(∼2 mg) was added after 1 h]. Volatiles were evaporated, the residue
was dissolved (H2O), and the aqueous solution was washed (CH2Cl2,
3×). The aqueous phase was evaporated, and the residue was subjected
to RP-HPLC (10 f 40% CH3CN/H2O; 2.8 mL/min, 80 min) to give
adenine (∼4%, tR ) 38.0 min), homoadenosine (28b, ∼47%; tR ) 40.3
min), 29 (∼37%, tR ) 47.6 min), and an unidentified product (∼12%,
tR ) 61.8 min). Data for compound 29:32 UV 260 nm; 1H NMR
(Me2SO-d6) δ 1.82 (dd, J ) 12.8, 6.4 Hz, 2H), 3.49 (m, t after D2O
ex, J ) 6.4 Hz, 2H), 3.87 (m, 1H), 4.25 (m, 2H), 4.53 (t, J ) 4.8 Hz,
1H, ex), 5.79 (d, J ) 1.2 Hz, 1H), 5.88 (m, 2H, ex), 7.33 (br s, 2H,
ex), 8.13 (s, 1H), 8.21 (s, 1H); 13C NMR (Me2SO-d6) δ 31.73, 57.83,
75.89, 79.94, 81.46, 89.48, 118.73, 139.72, 148.58, 152.30, 156.01;
HRMS (FAB) m/z 282.1201 (5, MH+ [C11H16N5O4] ) 282.1202).
9-(5-Deoxy-3-deuterio-â-D-xylo-hexofuranosyl)adenine (3′-[2H]-
29). Treatment of 27b (10 mg, 0.03 mmol) with Bu3SnD (as described
for 29) and RP-HPLC gave adenine, homoadenosine (28b), 3′-[2H]29,
and an unidentified product with yield ratios and retention times similar
to those described for 29. Data for 3′-[2H]29 (3 mg, 35%): UV max
260 nm; 1H NMR (Me2SO-d6) all peaks such as those for 29 except no
1
(lit.25d 265-268 °C dec); UV max 259 nm; H NMR (Me2SO-d6) δ
1.29, 1.50 (2 × s, 2 × 3H), 1.61-1.70 (dd, J ) 13.7, 6.0 Hz, 1H),
1.72-1.81 (dd, J ) 13.7, 7.1 Hz, 1H), 3.38 (dd, J ) 11.2, 5.6 Hz,
2H), 4.20 (td, J ) 7.1, 3.3 Hz, 1H), 4.50 (t, J ) 5.0 Hz, 1H, ex), 4.87
(dd, J ) 6.2, 3.3 Hz, 1H), 5.47 (dd, J ) 6.2, 2.7 Hz, 1H), 6.07 (d, J
) 2.7 Hz, 1H), 7.32 (br s, 2H, ex), 8.14 (s, 1H), 8.30 (s, 1H); 13C
NMR (Me2SO-d6) δ 25.27, 27.03, 36.26, 57.14, 82.95, 83.03, 83.71,
88.46, 113.36, 119.07, 139.92, 148.94, 152.76, 156.12; HRMS (FAB)
m/z 322.1512 (17, MH+ [C14H20N5O4] ) 322.1515).
9-(5-Deoxy-2,3-O-isopropylidene-6-O-nitro-â-D-ribo-hexofurano-
syl)adenine (27a). Protection of 27b17b (326 mg, 1 mmol) (as described
for 28b f 28a) [with chromatography (5% MeOH/CH2Cl2)] gave 27a
1
(293 mg, 80%): UV max 259 nm; H NMR δ 1.37, 1.60 (2 × s, 2 ×
3H), 2.15-2.24 (dd, J ) 11.7, 6.0 Hz, 2H), 4.26-4.35 (m, 1H), 4.42-
4.52 (m, 2H), 5.01 (dd, J ) 6.3, 3.9 Hz, 1H), 5.53 (dd, J ) 6.3, 2.2
Hz, 1H), 5.83 (br s, 2H, ex), 6.01 (d, J ) 2.2 Hz, 1H), 7.87 (s, 1H),
8.32 (s, 1H); 13C NMR δ 25.36, 27.15, 30.79, 69.55, 83.44, 83.85,
84.12, 90.52, 114.73, 118.82, 140.25, 149.57, 153.11, 155.60; HRMS
(FAB) m/z 367.1381 (27, MH+ [C14H19N6O6] ) 367.1366).
(48) Ryan, K. J.; Arzoumanian, H.; Acton, E. M.; Goodman, L. J. Am.
Chem. Soc. 1964, 86, 2503-2508.